A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.

This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis

Inclusion Criteria:

• Polyarticular (both rheumatoid factor positive and rheumatoid factor negative),oligoarticular and extended oligoarticular JIA for ≥3 months meeting the International League of Associations for Rheumatology (ILAR) criteria for Juvenile Idiopathic Arthritis (JIA)
• Subjects with Systemic JIA with active arthritis in at least 1 joint but without active systemic features are eligible
• ≥2 years of age and <18 years of age prior to the Baseline visit
• Body weight ≥10 kg at the Baseline visit
• Candidate for chronic NSAID therapy in the Investigator's judgment

Exclusion Criteria:

• Psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis types of JIA
• Active systemic features over the prior 12 weeks in children with systemic Juvenile Idiopathic Arthritis (JIA)
• Subjects with psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis should be excluded
• Subjects with active Systemic JIA should not be enrolled